Competitor Analysis: HDL Raising Therapies : Market Research Report

Competitor Analysis: HDL Raising Therapies

Published: Sep. 14, 2008 - 30 Pages

Index: Cholesteryl Ester Transfer Protein (CETP) Inhibitors; Niacin-Related Compounds; Apolipoprotein A-I (Apo A-I) and HDL Mimetics (Reverse Cholesterol Transport)

Abstract

The Competitive Intelligence Report HDL Raising Therapies as of September 2008 provides a competitor analysis in the development pipeline of novel emerging treatment modalities to raise HDL for treatment of dyslipidemia and atherosclerosis. Several targets and approaches for raising high density lipoprotein cholesterol (HDL-C) are evaluated for competitive projects:

Cholesteryl Ester Transfer Protein (CETP) Inhibitors;
Niacin-Related Compounds (nicotinic acid receptor agonists);
Apolipoprotein A-I (apo A-I), reconstituted HDL and HDL Mimetics

Data from epidemiological studies suggest that high density lipoprotein (HDL) provide protection against atherosclerosis. This property is primarily attributed to HDL’s involvement in cholesterol mobilization from peripheral tissues and reverse cholesterol transport for hepatic extraction of cholesterol. Other properties include HDL’s anti-inflammatory, antioxidant, antithrombotic and vasoprotective activities. At present, the only approved and marketed pharmaceutical with an HDL raising effect is niacin (nicotinic acid; vitamin B3). However, the HDL raising effect of niacin is rather modest (up to 26 %) and importantly, its activity is associated with the side effect of flushing. Abbott had revenues of more than US$ 600 mln with its niacin based products. Next generation niacin-related products aim at reducing flushing by improved galenical formulations, combination with flushing inhibitors and fixed dose combination with statins.

Inhibitors of cholesteryl ester transfer protein (CETP) hold the promise of increasing HDL by more than 100 %. The most advanced compounds are now in phase III development and so far have not been associated with increased blood pressure. This side effect had urged Pfizer to abandon its first-in-class CETP inhibitor torcetrapib in advanced phase III.

An obvious, but technologically difficult approach is to infuse exogenous reconstituted HDL or HDL mimetic. Alternatively, compounds which can increase the expression of apolipoprotein A-I (apo A-I), a main constituent of HDL), could induce the same effect. A phase II proof-of-concept study with reconstituted apo A-I Milano demonstrated an extremely rapid effect on reversing atherosclerosis as measured by intravascular ultrasound. This finding stimulated activities around apo A-I, but progress was slow mainly due to manufacturing difficulties. Currently, seven approaches to raise HDL are in clinical trials followed by quite a number of preclinical projects.

The Competitor Analysis HDL Raising Therapies also provides the R&D pipelines for HDL raising therapies of major players from Big Pharma and specialty biotech companies.

The report includes a compilation of current active projects in research and development of novel HDL Raising Therapies. Competitor projects are listed in a tabular format providing Information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Therapeutic Area,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/14/2012 - 30

Competitor Analysis: HDL Raising Therapies

Table of Contents

Abstract